Low Debt LevelsRamm Pharma's minimal reliance on debt provides financial stability and flexibility, reducing risk and interest burden, which is beneficial for long-term growth.

Strong Equity PositionA strong equity position indicates a solid financial foundation, allowing Ramm Pharma to withstand economic fluctuations and invest in growth opportunities.

Innovative Business ModelRamm Pharma's focus on innovation in pharmaceuticals positions it well for capturing market share in niche therapeutic areas, supporting long-term growth.

Bears Say

Cash Flow ChallengesPersistent cash flow challenges limit Ramm Pharma's ability to invest in R&D and operations, potentially hindering growth and sustainability.

Declining RevenueA decline in revenue indicates potential market share loss or demand issues, which could affect Ramm Pharma's long-term viability and competitive position.

Operational LossesOngoing operational losses suggest inefficiencies and financial strain, challenging Ramm Pharma's ability to achieve profitability and sustain operations.

Ramm Pharma News

RAMM Pharma Gains Shareholder Approval for Strategic Investment

An announcement from Ramm Pharma ( ($TSE:RAMM) ) is now available. RAMM Pharma Corp. has received minority shareholder...

3M ago

RAMM Pharma Corp. Details Strategic Investment in Global South

The latest announcement is out from Ramm Pharma ( ($TSE:RAMM) ). RAMM Pharma Corp. has announced additional details...

4M ago

RAMM Pharma Addresses Postal Delays for Shareholder Meeting Materials

Ramm Pharma ( ($TSE:RAMM) ) has issued an announcement. RAMM Pharma Corp. has informed its shareholders about potential...

4M ago

RAMM Pharma Explores Sale of Italian Subsidiary Canapar

Ramm Pharma ( ($TSE:RAMM) ) has provided an announcement. RAMM Pharma Corp. is considering the sale of its...

1y ago

Ramm Pharma Updates on Legal Dispute Outcome

Ramm Pharma (TSE:RAMM) has released an update. Ramm Pharma Corp. has announced that the Ontario Superior Court of...

1y ago

RAMM

RAMM Pharma Corp. Awaits Key Litigation Verdict

Ramm Pharma (TSE:RAMM) has released an update. RAMM Pharma Corp. has recently concluded a trial concerning a multimillion-dollar...

2y ago

RAMM

RAMM Pharma Expands with Botanical Supplements

Ramm Pharma Corp (TSE:RAMM) has released an update. RAMM Pharma Corp., a company traditionally known for cannabis-based products,...

2y ago

RAMM

RAMM Pharma Cancels Planned Private Placement

Ramm Pharma Corp (TSE:RAMM) has released an update. RAMM Pharma Corp., a leader in cannabinoid pharmacology, has cancelled...

2y ago

RAMM

RAMM FAQ

What was Ramm Pharma’s price range in the past 12 months?

Ramm Pharma lowest stock price was C$0.01 and its highest was C$0.25 in the past 12 months.

What is Ramm Pharma’s market cap?

Ramm Pharma’s market cap is C$2.98M.

When is Ramm Pharma’s upcoming earnings report date?

Ramm Pharma’s upcoming earnings report date is Feb 26, 2026 which is in 3 days.

How were Ramm Pharma’s earnings last quarter?

Ramm Pharma released its earnings results on Sep 27, 2025. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.

Is Ramm Pharma overvalued?

According to Wall Street analysts Ramm Pharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ramm Pharma pay dividends?

Ramm Pharma does not currently pay dividends.

What is Ramm Pharma’s EPS estimate?

Ramm Pharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ramm Pharma have?

Ramm Pharma has 119,389,320 shares outstanding.

What happened to Ramm Pharma’s price movement after its last earnings report?

Ramm Pharma reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Ramm Pharma?

Currently, no hedge funds are holding shares in TSE:RAMM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ramm Pharma

RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.